Lance Ostrom

Medicine · Health Sciences

6h-index1.3kcitations22works0.02yr avg
OpenAlex↗Google Scholar↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Cancer Mechanisms and Therapy(7), Microtubule and mitosis dynamics(6), Hedgehog Signaling Pathway Studies(4), Cancer Cells and Metastasis(3), Wnt/β-catenin signaling in development and cancer(3)

Publications22 total

Supplementary Figure Legends from Discovery and Optimization of HKT288, a Cadherin-6–Targeting ADC for the Treatment of Ovarian and Renal Cancers
2023Open Access
Data from Discovery and Optimization of HKT288, a Cadherin-6–Targeting ADC for the Treatment of Ovarian and Renal Cancers
2023Open Access
Supplementary Figures 1 through 7 from Discovery and Optimization of HKT288, a Cadherin-6–Targeting ADC for the Treatment of Ovarian and Renal Cancers
2023Open Access
Supplementary Figure Legends from Discovery and Optimization of HKT288, a Cadherin-6–Targeting ADC for the Treatment of Ovarian and Renal Cancers
2023Open Access
Supplementary Material and Methods from Discovery and Optimization of HKT288, a Cadherin-6–Targeting ADC for the Treatment of Ovarian and Renal Cancers
2023Open Access
Supplementary Tables 1 through 11 from Discovery and Optimization of HKT288, a Cadherin-6–Targeting ADC for the Treatment of Ovarian and Renal Cancers
2023Open Access
Data from Discovery and Optimization of HKT288, a Cadherin-6–Targeting ADC for the Treatment of Ovarian and Renal Cancers
2023Open Access
Supplementary Figures 1 through 7 from Discovery and Optimization of HKT288, a Cadherin-6–Targeting ADC for the Treatment of Ovarian and Renal Cancers
2023Open Access
Supplementary Tables 1 through 11 from Discovery and Optimization of HKT288, a Cadherin-6–Targeting ADC for the Treatment of Ovarian and Renal Cancers
2023Open Access
Supplementary Material and Methods from Discovery and Optimization of HKT288, a Cadherin-6–Targeting ADC for the Treatment of Ovarian and Renal Cancers
2023Open Access
Discovery and Optimization of HKT288, a Cadherin-6–Targeting ADC for the Treatment of Ovarian and Renal Cancers
Cancer Discovery·2017· 52 citedOpen Access
Abstract 872: In vivo activity of a novel CDH6 targeting antibody-drug conjugate, including population-scale ovarian PDX clinical trial
Cancer Research·2016
Abstract 2974: Targeting cadherin-6 (CDH6) with an antibody-drug conjugate for the treatment of ovarian and renal cancer
Cancer Research·2016· 1 cited
Multivalent nanobodies targeting death receptor 5 elicit superior tumor cell killing through efficient caspase induction
mAbs·2014· 104 citedOpen Access
Interfering with Resistance to Smoothened Antagonists by Inhibition of the PI3K Pathway in Medulloblastoma
Science Translational Medicine·2010· 553 cited
Inhibition of tumorigenesis driven by different Wnt proteins requires blockade of distinct ligand-binding regions by LRP6 antibodies
Proceedings of the National Academy of Sciences·2010· 153 citedOpen Access
Gene expression analysis in human hair bulbs as a potential pharmacodynamic readout in the LDE225 clinical program.
Journal of Clinical Oncology·2010· 1 cited
Abstract 4290: The smoothened antagonist NVP-LDE225 targets stroma and cancer stem cells in primary human pancreatic tumor xenografts
Cancer Research·2010· 4 cited
Abstract 1976: The discovery of mechanisms of resistance to SMO antagonists and the therapeutic implications
Cancer Research·2010
Abstract A41: The preanalytic impact of simulated ischemia on PI3K biomarkers
Molecular Cancer Therapeutics·2009· 1 cited
page 1 of 2Next →

Frequent Co-authors

Rebecca Mosher(17), William R. Sellers(16), Sanela Bilic(14), Seth A. Ettenberg(13), Hui Gao(13), Carl Uli Bialucha(13), Yeonju Shim(13), Matthew J. Meyer(13), Emma Lees(13), Parmita Saxena(12), Xiamei Zhang(12), Tiancen Hu(12), Ivana Liric Rajlic(12), Vladimı́r Čápka(12), Meghan Flaherty(12), Keith G. Mansfield(12), Anne Serdakowski London(12), William R. Tschantz(12), Markus Kurz(12), Duc T. Nguyen(12)